Interplay between inflammation and cancer.
ANGPTL4, angiopoietin-like 4
CDH1, cadherin 1
COX, cyclooxygenase
Cancer
EMT, epithelail to mesenchymal transition
EP, receptor - prostaglandin receptor
GI, gastrointensinal cancer
IL-6, interleukin 6
Inflammation
MPO, myeloperoxidase
NADPH, nicotynamide adenine dinucleotide phosphate hydrogen
NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells
NK, natural killer cells
NO, nitric oxide
NSAIDs, non-steroidal anti-inflammatory drugs
PGE2, prostaglandin E2
PTHrP, parathyroid hormone related protein
RNS, reactive nitrogen species
ROS, reactive oxigen species
STAT3, signal transducer and activator of transcription 3
TGF-β, transforming growth factor β
TGFBRII, transforming growth factor, beta receptor II
TNF-α, tumour necrosis factor α
TNFR1, Tumor necrosis factor receptor 1
TNFR2, Tumor necrosis factor receptor 2
Tumor reccurence
VEGF, vascular endothelail growth factor
bFGF, fibroblast growth factor
iNOS, inducible nitric oxide synthase
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
13
09
2019
revised:
20
02
2020
accepted:
02
04
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
ppublish
Résumé
Tumor-promoting inflammation is one of the hallmarks of cancer. It has been shown that cancer development is strongly influenced by both chronic and acute inflammation process. Progress in research on inflammation revealed a connection between inflammatory processes and neoplastic transformation, the progression of tumour, and the development of metastases and recurrences. Moreover, the tumour invasive procedures (both surgery and biopsy) affect the remaining tumour cells by increasing their survival, proliferation and migration. One of the concepts explaining this phenomena is an induction of a wound healing response. While in normal tissue it is necessary for tissue repair, in tumour tissue, induction of adaptive and innate immune response related to wound healing, stimulates tumour cell survival, angiogenesis and extravasation of circulating tumour cells. It has become evident that certain types of immune response and immune cells can promote tumour progression more than others. In this review, we focus on current knowledge on carcinogenesis and promotion of cancer growth induced by inflammatory processes.
Identifiants
pubmed: 32372882
doi: 10.1016/j.rpor.2020.04.004
pii: S1507-1367(20)30060-2
pmc: PMC7191124
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
422-427Informations de copyright
© 2020 The Author(s).
Références
Cancer Res. 2000 Sep 15;60(18):5021-6
pubmed: 11016622
Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000
pubmed: 21508345
Clin Cancer Res. 1999 Jun;5(6):1411-5
pubmed: 10389926
Cell. 2005 Feb 25;120(4):497-512
pubmed: 15734682
Oncol Rep. 2014 Oct;32(4):1521-30
pubmed: 25109834
Cell. 2008 Jun 13;133(6):1019-31
pubmed: 18555778
Prog Mol Biol Transl Sci. 2016;144:69-117
pubmed: 27865469
J Biol Chem. 2002 Jul 5;277(27):24571-8
pubmed: 11964407
Br J Cancer. 2001 Aug 17;85(4):490-2
pubmed: 11506484
Cancer Res. 1989 Apr 15;49(8):1996-2001
pubmed: 2702641
Cancer Res. 2014 Nov 1;74(21):5963-77
pubmed: 25189528
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Semin Cancer Biol. 2012 Feb;22(1):33-40
pubmed: 22210179
Cell Cycle. 2005 Feb;4(2):217-20
pubmed: 15655344
Carcinogenesis. 1993 Aug;14(8):1555-9
pubmed: 7689037
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nature. 2000 Feb 24;403(6772):859-66
pubmed: 10706276
J Immunol. 2010 Apr 15;184(8):4062-8
pubmed: 20368286
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i104-8
pubmed: 21339211
Eur J Cancer. 2006 Apr;42(6):735-44
pubmed: 16527478
Cell. 1998 May 29;93(5):705-16
pubmed: 9630216
Carcinogenesis. 1990 Aug;11(8):1441-4
pubmed: 2167184
Mutat Res. 1999 Jul 15;443(1-2):37-52
pubmed: 10415430
Cancer Cell. 2008 Jan;13(1):23-35
pubmed: 18167337
Annu Rev Pharmacol Toxicol. 2001;41:661-90
pubmed: 11264472
Clin Transl Immunology. 2016 Apr 29;5(4):e76
pubmed: 27195119
Clin Cancer Res. 2008 Mar 1;14(5):1325-32
pubmed: 18316551
Lancet. 2007 May 12;369(9573):1603-13
pubmed: 17499602
Science. 1985 Mar 8;227(4691):1231-3
pubmed: 3975611
Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400
pubmed: 9184771
Cancer Res. 1998 Feb 1;58(3):409-12
pubmed: 9458081
Cancer. 1994 Nov 15;74(10):2885-8
pubmed: 7954252
Cancer. 1993 Aug 1;72(3 Suppl):962-70
pubmed: 8334671
J Clin Invest. 2002 Sep;110(5):651-8
pubmed: 12208866
Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):48-58
pubmed: 15967161
Rep Pract Oncol Radiother. 2019 Sep-Oct;24(5):428-431
pubmed: 31537978
Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2
pubmed: 11866137
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Trends Mol Med. 2008 Mar;14(3):109-19
pubmed: 18261959
J Immunother. 2012 Feb-Mar;35(2):179-88
pubmed: 22306906
FASEB J. 1999 Jul;13(10):1121-36
pubmed: 10385604
Exp Cell Res. 1965 Mar;37:614-36
pubmed: 14315085
Cancer Res. 2012 Mar 1;72(5):1290-300
pubmed: 22253230
Gastroenterology. 1999 Jun;116(6):1319-29
pubmed: 10348815
Lancet. 1987 Nov 28;2(8570):1229-32
pubmed: 2890853
World J Gastroenterol. 2015 Mar 21;21(11):3174-83
pubmed: 25805923
FEBS Lett. 1995 Dec 4;376(3):207-10
pubmed: 7498543
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Contrib Microbiol. 2006;13:1-15
pubmed: 16627956
Oncotarget. 2015 Oct 6;6(30):29296-310
pubmed: 26313265
PLoS One. 2015 Jul 24;10(7):e0132710
pubmed: 26207636
J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
pubmed: 20858887
Nature. 2005 Aug 4;436(7051):642
pubmed: 16079833
Am J Pathol. 1993 Aug;143(2):381-9
pubmed: 8393616
Oncotarget. 2014 Aug 15;5(15):6267-79
pubmed: 25026286
Oncogene. 2006 Nov 9;25(53):7019-28
pubmed: 16732324
Oncol Rep. 2017 Mar;37(3):1873-1882
pubmed: 28098875
Oncol Rep. 2002 May-Jun;9(3):521-4
pubmed: 11956620
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643230
J Thorac Oncol. 2010 Dec;5(12):2024-36
pubmed: 21155185
Clin Sci (Lond). 2011 Sep;121(6):233-51
pubmed: 21615335
Mol Cancer Ther. 2007 Oct;6(10):2609-17
pubmed: 17938257
Nat Commun. 2014 Sep 17;5:4944
pubmed: 25229256
Cancer Res. 2008 Jan 1;68(1):323-8
pubmed: 18172326
Oncogene. 2004 Mar 11;23(10):1902-10
pubmed: 14661063
Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78
pubmed: 10722929
J Exp Med. 2000 Dec 18;192(12):1809-18
pubmed: 11120777
Lancet Oncol. 2001 Mar;2(3):149-56
pubmed: 11902565
Am J Physiol Gastrointest Liver Physiol. 2003 Dec;285(6):G1171-80
pubmed: 12919943
Cancer Res. 2005 Jun 15;65(12):5211-20
pubmed: 15958566
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
Cell. 1995 May 19;81(4):495-504
pubmed: 7758105
Int J Cancer. 2000 Jan 15;85(2):182-8
pubmed: 10629075
Cell. 2008 Apr 4;133(1):66-77
pubmed: 18394990
Gut. 2003 Apr;52(4):502-6
pubmed: 12631658
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Arch Biochem Biophys. 2003 Sep 1;417(1):3-11
pubmed: 12921773
Microsc Res Tech. 2000 Aug 1;50(3):184-95
pubmed: 10891884
Mol Oncol. 2017 Jul;11(7):792-804
pubmed: 28649800